REGENXBIO schedules October 20 event: REGENXBIO stock gains 8.87 percent

Published on 10/20/2026 at 19:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sura-vec event was set for October 20, 2026. REGENXBIO stock costs EUR 6.70 on October 20, 2026, up 8.87 percent versus Tradegate close.

Reporting date October 20, 2026

REGENXBIO scheduled its Sura-vec investor event for October 20, 2026.
Second-quarter 2026 revenue reached USD 108.02 million, USD 10.39 million above consensus.
REGENXBIO stock costs EUR 6.70 at Lang & Schwarz on October 20, 2026 at 7:49 p.m. CEST, 8.87 percent above the Tradegate close of October 16, 2026.
The next quarterly update is listed for November 5, 2026.

RGNX, US75901B1070, Illustration mit AI erstellt.

REGENXBIO (US75901B1070) had scheduled its Sura-vec investor event for October 20, 2026, highlighting surabgene lomparvovec in wet age-related macular degeneration, according to REGENXBIO. The stock was trading at EUR 6.70 at Lang & Schwarz on October 20, 2026 at 7:49 p.m. CEST, up 8.87 percent versus the Tradegate close of October 16, 2026 at EUR 6.15.

Revenue beat adds financial support

The company's second-quarter 2026 revenue reached USD 108.02 million, compared with consensus of USD 97.63 million, a difference of USD 10.39 million. MarketBeat reported that adjusted earnings per share were USD 0.43, above the USD 0.08 consensus estimate, for the quarter ended June 30, 2026.

Stock stays below the yearly high

At EUR 6.70, the Lang & Schwarz price stood 53.79 percent below the 52-week high of EUR 14.50 and 40.70 percent above the 52-week low of EUR 4.76. The primary Nasdaq listing last traded at USD 7.53 on October 20, 2026 at 1:56 p.m. ET, while the year-low and year-high levels were USD 5.46 and USD 16.19.

Analyst targets remain a counterweight

Investing.com reported that Mizuho initiated coverage on October 5, 2026 with an Outperform rating and a USD 22.00 price target. That target lies 192.16 percent above the USD 7.53 Nasdaq price. The rating also identified RGX-202 and ABBV-RGX-314 as key assets, while clinical and regulatory execution remain material factors.

What dates shape the next step?

wallstreetONLINE lists November 5, 2026 as the next quarterly update. The October 20 event therefore sits between the June 30 reporting period and the next scheduled corporate date.

Market value and trading context

REGENXBIO's market capitalization was USD 497.1 million as of October 20, 2026, with a negative price-to-earnings ratio of 1.99. Its gene therapy pipeline covers retinal, neuromuscular and neurodegenerative diseases, according to the company profile.

REGENXBIO stock was trading at EUR 6.70 at Lang & Schwarz on October 20, 2026 at 7:49 p.m. CEST, 8.87 percent above the Tradegate close of October 16, 2026 at EUR 6.15. The further course of trading is shown by the continuously updated real-time quote of REGENXBIO stock.